Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
← catalyst calendarSponsored by ALK-Abelló A/S (industry) · ALK-B.CO — their whole pipeline →. With Parexel.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
209actual
Sites
42
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-07 | actual | When the study began enrolling |
| Primary completion | 2026-03-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-05 | actual | The whole study's end, after follow-up |
| First posted | 2022-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Peanut Allergy
Interventions
- Biological: Peanut SLIT-tablet
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart 1 and 2: Dose tolerability response rate
measured 2 weeks per dose
Part 3: TD-600 response rate
measured After 24 weeks of maintenance treatment, up to 48 weeks.
Permalink · ALK-B.CO's whole pipeline · Catalyst calendar · Every registered study · What changed